Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.
ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
The company is based in Fremont, California.
ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 24 | -0.01 Increased by +98.17% | - |
| Aug 14, 24 | -0.09 Increased by +86.93% | - |
| May 17, 24 | -0.40 Decreased by -573.33% | - |
| Mar 13, 24 | -0.39 Decreased by -161.20% | - |
| Nov 15, 23 | -0.82 Decreased by -643.73% | -0.04 Decreased by -1.95 K% |
| Aug 14, 23 | -0.68 Decreased by -1.04 K% | -0.06 Decreased by -1.04 K% |
| May 15, 23 | -0.06 Increased by +70.00% | -0.05 Decreased by -20.00% |
| Mar 31, 23 | -0.15 Increased by +51.61% | -0.15 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 389.28 K Increased by +2.35 K% | -186.56 K Increased by +94.38% | Decreased by -47.93% Increased by +99.77% |
| Jun 30, 24 | 117.14 K Increased by +1.82 K% | -1.01 M Increased by +55.26% | Decreased by -864.46% Increased by +97.67% |
| Mar 31, 24 | 1.21 K Decreased by -99.06% | -3.93 M Decreased by -5.25 K% | Decreased by -326.39 K% Decreased by -569.24 K% |
| Dec 31, 23 | 2.17 K Decreased by -99.63% | -3.11 M Increased by +30.88% | Decreased by -143.69 K% Decreased by -18.70 K% |
| Sep 30, 23 | 15.88 K Decreased by -62.42% | -3.32 M Increased by +12.15% | Decreased by -20.89 K% Decreased by -133.77% |
| Jun 30, 23 | 6.11 K Decreased by -98.05% | -2.26 M Decreased by -16.24% | Decreased by -37.05 K% Decreased by -5.85 K% |
| Mar 31, 23 | 128.27 K Increased by +399.89% | -73.53 K Increased by +98.79% | Decreased by -57.33% Increased by +99.76% |
| Dec 31, 22 | 588.99 K Increased by +1.66 K% | -4.50 M Increased by +43.26% | Decreased by -764.17% Decreased by -103.64% |